CALCIMEDICA
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D, who identified Orai1 as the CRAC channel subunit in 2006.
CALCIMEDICA
Industry:
Health Care Information Technology Life Science
Founded:
2006-12-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.calcimedica.com
Total Employee:
11+
Status:
Active
Contact:
8589525490
Email Addresses:
[email protected]
Total Funding:
95.46 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Current Advisors List
Current Employees Featured
Founder
Investors List
Quark Venture
Quark Venture investment in Series D - CalciMedica
Sanderling Ventures
Sanderling Ventures investment in Series D - CalciMedica
Global health sciences venture fund
Global health sciences venture fund investment in Series D - CalciMedica
Valence Life Sciences
Valence Life Sciences investment in Series D - CalciMedica
Valence Life Sciences
Valence Life Sciences investment in Series C - CalciMedica
Mesa Verde Venture Partners
Mesa Verde Venture Partners investment in Series C - CalciMedica
Bering Capital
Bering Capital investment in Series C - CalciMedica
Sanderling Ventures
Sanderling Ventures investment in Series C - CalciMedica
Sanderling Ventures
Sanderling Ventures investment in Series C - CalciMedica
SR One
SR One investment in Series C - CalciMedica
Official Site Inspections
http://www.calcimedica.com Semrush global rank: 10.21 M Semrush visits lastest month: 25
- Host name: calcimedicadev.tempurl.host
- IP address: 140.82.50.38
- Location: San Jose United States
- Latitude: 37.3387
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95113
More informations about "CalciMedica"
About Us - CalciMedica
CalciMedica’s current drug development efforts build on nearly two decades of research into the role of CRAC channels in the immune response as well as preclinical and clinical research …See details»
CalciMedica - Crunchbase Company Profile & Funding
CalciMedica is engaged in the discovery and development of small molecule drugs for the treatment of inflammatory and autoimmune disorders. …See details»
CalciMedica, Inc. - AnnualReports.com
CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary …See details»
CalciMedica - LinkedIn
CalciMedica | 1,138 followers on LinkedIn. Leader in the development of CRAC channel inhibitor drugs for inflammatory diseases | CalciMedica is a privately held, clinical stage biotechnology ...See details»
CalciMedica, Inc. (CALC) Company Profile & Overview - Stock …
Oct 31, 2024 CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and …See details»
Graybug and CalciMedica Enter into Definitive Merger Agreement
Nov 21, 2022 About the Proposed Transaction, Management and Organization Graybug equity holders are expected to collectively own approximately 29% of the combined company, and …See details»
CalciMedica - Funding, Financials, Valuation & Investors
CalciMedica is registered under the ticker NASDAQ:CALC . CalciMedica is funded by 13 investors. Aisling Capital and Sanderling Ventures are the most recent investors. CalciMedica …See details»
CalciMedica, Inc. (CALC) - Yahoo Finance
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate …See details»
CalciMedica Announces Relisting on Nasdaq
Jun 12, 2023 Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included …See details»
Graybug and CalciMedica Enter into Definitive Merger Agreement
Nov 21, 2022 Graybug Vision, Inc.; CalciMedica Inc. – Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica’s pipeline of first-in …See details»
CalciMedica, Inc. (CALC) - Yahoo Finance
CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium …See details»
CalciMedica Reports 2023 Financial Results and Provides Clinical ...
Mar 28, 2024 Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included …See details»
CalciMedica Announces FDA Clearance of IND Application for …
Feb 13, 2024 CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium …See details»
CalciMedica Announces Private Placement of up to Approximately …
Jan 22, 2024 CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium …See details»
CALC.OQ - | Stock Price & Latest News | Reuters
Nov 4, 2024 CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for …See details»
Kidney - CalciMedica
Auxoraâ„¢ has the potential to treat severe acute kidney injury, also known as acute renal failure, and limit its associated morbidity and mortality, including progression to chronic kidney …See details»
CalciMedica Reports Third Quarter 2024 Financial Results and …
Sep 30, 2024 LA JOLLA, Calif., Nov. 13, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on …See details»
Lung - CalciMedica
Patients suffering from moderate and severe ARDS as a result of COVID-19 infection who were treated with Auxoraâ„¢ in addition to standard of care recovered faster than those on standard …See details»
Technologies & Pipeline - CalciMedica
CalciMedica’s lead pipeline candidate, Auxoraâ„¢, is a proprietary, intravenous-formulated, small molecule CRAC channel inhibitor. Auxoraâ„¢ has been studied in four Phase 2 clinical trials, …See details»